US Bancorp DE Boosts Stock Position in Novavax, Inc. (NASDAQ:NVAX)

US Bancorp DE grew its holdings in shares of Novavax, Inc. (NASDAQ:NVAX) by 3,538.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 12,299 shares of the biopharmaceutical company’s stock after buying an additional 11,961 shares during the quarter. US Bancorp DE’s holdings in Novavax were worth $155,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Amalgamated Bank raised its holdings in Novavax by 26.9% in the second quarter. Amalgamated Bank now owns 4,887 shares of the biopharmaceutical company’s stock valued at $62,000 after acquiring an additional 1,036 shares in the last quarter. Ensign Peak Advisors Inc raised its stake in shares of Novavax by 3.0% in the 2nd quarter. Ensign Peak Advisors Inc now owns 44,900 shares of the biopharmaceutical company’s stock valued at $568,000 after purchasing an additional 1,300 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Novavax by 38.1% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,790 shares of the biopharmaceutical company’s stock valued at $77,000 after purchasing an additional 1,598 shares in the last quarter. Edgestream Partners L.P. lifted its position in shares of Novavax by 23.7% during the first quarter. Edgestream Partners L.P. now owns 12,753 shares of the biopharmaceutical company’s stock worth $61,000 after purchasing an additional 2,447 shares during the last quarter. Finally, Banque Cantonale Vaudoise grew its stake in Novavax by 500.0% in the second quarter. Banque Cantonale Vaudoise now owns 3,000 shares of the biopharmaceutical company’s stock worth $38,000 after purchasing an additional 2,500 shares in the last quarter. 53.04% of the stock is currently owned by hedge funds and other institutional investors.

Novavax Trading Up 1.4 %

Shares of NASDAQ NVAX opened at $7.32 on Friday. Novavax, Inc. has a 12-month low of $3.53 and a 12-month high of $23.86. The company has a market cap of $1.17 billion, a price-to-earnings ratio of -3.24 and a beta of 2.10. The stock’s 50 day simple moving average is $11.35 and its 200 day simple moving average is $12.38.

Novavax (NASDAQ:NVAX) last posted its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.76) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.11. The company had revenue of $84.51 million during the quarter, compared to the consensus estimate of $65.80 million. The business’s quarterly revenue was down 54.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.26) earnings per share. As a group, equities analysts forecast that Novavax, Inc. will post -1.01 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have issued reports on NVAX shares. JPMorgan Chase & Co. upped their price objective on Novavax from $8.00 to $9.00 and gave the company an “underweight” rating in a research note on Monday, August 12th. HC Wainwright reissued a “buy” rating and set a $19.00 price target on shares of Novavax in a research report on Tuesday. Jefferies Financial Group reduced their price objective on Novavax from $31.00 to $25.00 and set a “buy” rating on the stock in a research note on Wednesday, October 16th. Finally, B. Riley reiterated a “buy” rating and set a $26.00 target price (up previously from $23.00) on shares of Novavax in a research note on Thursday, October 10th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $17.83.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.